Head and Neck Diseases by Alexandros G.Sfakianakis: A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Τρίτη 20 Μαρτίου 2018

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

http:--www.tandfonline.com-templates-jsp

https:--www.ncbi.nlm.nih.gov-corehtml-pm

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Leuk Lymphoma. 2016 09;57(9):2212-5

Authors: Maddocks K, Hertlein E, Chen TL, Wagner AJ, Ling Y, Flynn J, Phelps M, Johnson AJ, Byrd JC, Jones JA

PMID: 26764527 [PubMed - indexed for MEDLINE]

http://ift.tt/2FRdBYs

Head and Neck Diseases by Alexandros G.Sfakianakis

Τρίτη 20 Μαρτίου 2018

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου